Neurenati Therapeutics
Neurenati Therapeutics is a Québec-based biotech company focused on developing innovative therapies for rare diseases, specifically Hirschsprung disease (HD). They are advancing a first-in-class combination therapy utilizing a growth factor, aiming to eliminate the need for surgery and minimize complications in newborns with HD. Their lead program, NEU-001, is designed to regenerate the enteric nervous system, potentially becoming a curative treatment.
Funding Round: Seed+
Funding Amount: $1.7M
Date: 04-Mar-2025
Investors: Genson Capital, Invest Quebec, (mandated by the Government of Quebec), Angels
Markets: Biotech, Therapeutics, Rare Diseases
HQ: Québec, Canada
Founded: 2020
Website: http://www.neurenati.com
LinkedIn: https://www.linkedin.com/company/neurenati
Twitter: https://twitter.com/neurenati
Crunchbase: https://www.crunchbase.com/organization/neurenati-therapeutics
Leave a Comment
Comments
No comments yet.